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Clinical manifestation of novel SPAST mutations
Research highlights:
 There are numerous mutations in the SPAST gene with a wide spectrum of clinical 
phenomenology
 We report 2 novel mutations (c.1732A>T p.R578X and c.1334G>C p.S445T)
affecting the AAA catalytic domain with quite different age at onset and some
difference in phenomenology
 Establishing genotype-phenotype correlations would promote the understanding of the
function of spastin under normal and pathological conditions
Introduction
Hereditary spastic paraplegia (HSP) is heterogeneous group of genetically inherited disorders
mainly characterized by spastic gait impairment [1]. It affects approximately 1.2 to 9.6 out of
100,000 individuals. There are more than 50 mutations which can be responsible for the 
development of uncomplicated or complicated (spastic paraplegia associated with additional 
neurologic or systemic abnormalities) forms, and there are several modes of inheritance. The 
most common causes of autosomal dominantly inherited cases, which account for 70-80% of 
all HSP forms in the Western countries, are mutations in the SPAST gene mapped to 2p22 [2]. 
All types of mutations (missense, nonsense, splicing site, deletions and insertions) have been 
detected in the SPAST gene at numerous loci with wide age range of onset. The gene product, 
spastin possesses 2 main structural domains: the microtubule interacting and trafficking 
domain (MIT) in the N-terminus, which is responsible for the association of spastin with 
microtubules, and the catalytic AAA domain at the C-terminus with ATPase activity [3]. The 
spastin-mediated severing of microtubules is particularly involved in axonal transport and 
axonal branching. The haploinsufficiency of spastin –  mainly caused by mutations in the 
AAA domain – is responsible for the progressive retrograde degeneration preferentially 
affecting long corticospinal axons with the consequential development of characteristic 
symptoms [3].
The aim of this study is to present the genotype-phenotype correlation of a previously 
unpublished novel mutation site in the SPAST gene, and furthermore to report a de novo
mutation leading to the development of characteristic symptoms in early childhood.
Case reports
The first case is a 47-year-old female patient who was first admitted to our neurology 
department with the aim of the diagnostic work-up of her unknown gait disorder in 2008. She
had already had some less expressed symptoms since her childhood, but without significant 
complaints. Her gait worsened progressively from 2007, it became more and more stiff. In 
addition to her motor symptoms, frequent urge to urinate and to have bowel functions both 
persisted since her childhood. Beyond tonsillectomy and dysmenorrhea, there were no other
relevant diseases in her case history. She did not suffer traumatic injury. With regard to her 
family history, her father is wheelchair-bound because of a similar gait disorder. On 
neurological examination, our female patient presented slight spasticity in her lower limbs 
considerably disturbing her gait. Her tendon reflexes were brisk with bilateral ankle clonus. 
With regard to pathological reflexes the patient presented Babinski and Hoffman's signs. 
There were no seeming alterations in cognitive functions, muscle strength, movement
coordination and sensation. The applied laboratory test (ions, inflammatory markers, complete
blood count, thyroid functions, vitamin B
12 
and folic acid) did not show any unequivocal 
abnormality. The skull, cervical and thoracic MRI scans revealed no pathognomonic 
abnormality. The lumbar MRI demonstrated multiple discopathy and signs of Scheuermann's 
disease without any stenosing effect. Cerebrospinal fluid diagnostics did not show any signs
of inflammation or immunological disorder. The examination of somatosensory evoked 
potentials demonstrated the preservation of sensory functions. The clinical picture and the 
positive family history raised the possibility of uncomplicated HSP (Figure 1a). The genetic 
testing for a disease-causing mutation in the SPAST gene (Centogene AG, Rostock, Germany) 
revealed heterozygous mutation in exon 17 (c.1732A>T p.R578X) not only in our patient, but
also in her father (Department of Medical Genetics, University of Szeged, Szeged, Hungary) 
(Figure 1b).
The second case is an 8-year-old boy who was born at term from the third, twin pregnancy of
his mother. The other twin died in utero in the first trimester of the pregnancy, but otherwise 
no complications were reported. His birth weight, length and head circumference were in the
normal range. He was first examined by a pediatric neurologist at the age of 18 months for 
delayed motor development, i.e., being unable to walk. No neurological abnormalities were 
detected at this first examination, but physiotherapy was recommended to catch up to his age. 
He began to walk, but at the age of 22 months minor gait disturbances and mild signs of 
weakness in the lower limbs appeared: he had a tottering gait and could not walk more than a 
few steps. Speech development was also delayed: his speech was restricted to only a few 
words. The first signs of spastic paraparesis appeared at the age of 26 months: spasticity was 
detected in both legs with brisk tendon reflexes and persisting Babinski sign. He was walking 
on his tiptoes. No ataxia could be detected. Evaluations of serum lactate and creatine kinase 
levels were normal. Spine and skull magnetic resonance imaging were performed at the age of
4 years, but no abnormalities were detected. The lack of morphological abnormalities in the 
central nervous system and the progressive spasticity in the lower limbs turned our attention 
to the possibility of hereditary spastic paraplegia. Genetic testing was also performed at 
Centogene AG (Rostock, Germany) and the results showed a de novo mutation in exon 11 of
the SPAST gene (c.1334G>C p.S445T), as no mutation was found in the parents (Figure 2a 
and 2b).
Discussion
Despite the intensive research activity, the pathomechanism of HSPs is not yet fully 
understood. With regard to the most commonly affected SPAST gene, there are numerous 
reported mutation sites with a relatively wide spectrum of age at onset (from the very early 
childhood to the sixties) and clinical manifestation [4]. The delineation of novel mutations in
the SPAST gene seems to be very important since the detailed description of clinical 
phenomenology would promote the understanding of structure-function relationship of the 
gene product, spastin. This case study reports 2 novel mutations, located within highly
conserved regions of the protein (Figure 1c and 2c). According to the HSP mutation database
(https://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=9&geneId=EG6683), 
None of the mutations (p.R578X and p.S445T) have been previously demonstrated. A
mutation-causing p.S445R amino acid change has already been described [4], but the p.S445T
change has not been previously reported. Although both genetic mutations affect the AAA 
domain of spastin – similarly to most of SPAST mutations – the clinical phenomenology is 
quite different.
With regard to our first patient, her symptoms, which mainly affect her gait and vegetative 
functions, persisted from her late childhood, but they became expressed only in her middle- 
age. These alterations are characteristic for uncomplicated cases. The closest known affected
site by a nonsense mutation (c.1741C>T p.R581X) causes similar symptoms (gait disorder 
with lower limb spasticity and brisk tendon reflexes, sphincter impairment), but slightly later
disease onset (the mean age is 28.5 years) [5].
The symptoms of the other patient developed in very early childhood and mainly 
characterized by lower limb weakness accompanied by gait disturbance. There are some 
available reports of SPAST mutations with an onset at the early childhood [4, 6], mainly 
affecting the 400 to 500 amino acids region of spastin, similar to our case. At the age of 8 
years, he attended a regular school and he was able to walk with ankle-foot orthosis and a 
walking stick. His cognitive skills are in the normal range, he performs well in the elementary
school. Although the age at onset is quite different from the previously reported case of 
p.S445R amino acid change in spastin – with a considerable disease worsening at late teenage
years – the clinical course shows some similarities: the case is described as a complicated
HSP form with walking difficulties with marked lower limb stiffness, and furthermore with
bladder, swallowing, breathing and speech dysfunctions [4].
Conclusion
In conclusion, the clinical description of novel mutations in the SPAST gene would 
accompany to the understanding of the functioning of the gene product, spastin, both under
normal and pathological conditions.
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Figure Legends
Figure 1. (a) Pedigree of the investigated family demonstrates that the investigated proband
(II/1) and her father (I/1) are the only affected individuals within the family.  (b) Direct
sequencing revealed a newly identified nonsense mutation. The affected patients carried the
mutation in a heterozygous form, while the investigated healthy family members carried wild
type  sequences  only.  (c)  The  identified  nonsense  mutation  is  located  within  a  highly
conserved region of the protein.
Figure 2. (a) Pedigree of the investigated family demonstrates that the investigated proband
(II/1) is the only affected individual within the family. (b) Direct sequencing revealed a novel
missense mutation, which is carried in a heterozygous form by the patient. (c) The identified
missense mutation is located within a highly conserved region of the protein.


